New Imaging Technique Improves Liver Cancer Staging
A new PET/CT scan shows greater accuracy in detecting liver cancer lesions than traditional imaging methods.
Updated on Oct. 20, 2026 in Cancer
Live Poll
Should medical systems prioritize new PET scanning technologies to improve cancer staging and treatment planning?
Researchers have found that [18F]FAPI PET/CT imaging detects significantly more primary and metastatic liver cancer lesions than standard [18F]FDG PET/CT scans. This diagnostic improvement led to staging changes for over half of patients in a recent study.
Why it matters
Accurate staging is critical for determining appropriate cancer treatments, as traditional methods may underestimate the extent of tumor spread. Using more sensitive imaging could improve clinical outcomes by allowing for earlier or more targeted interventions.
The study utilized [18F]FAPI PET/CT, which detected 96.7% of primary intrahepatic lesions compared to 60.0% by [18F]FDG PET/CT. Management plans were subsequently adjusted for 22 of 38 patients, representing 57.9% of the cohort.
The details
The study compared imaging findings against serum levels of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in 38 individuals. Researchers found that [18F]FAPI PET/CT detected 94.6% of lymph-node metastases and 78.8% of distant metastases, compared to 80.4% and 48.5% respectively for [18F]FDG PET/CT.
Timeline
The clinical trial was registered on March 30, 2023.
The findings were published on October 20, 2026.
The Big Picture
This study advances the clinical utility of [18F]FAPI PET/CT for hepatocellular carcinoma staging by demonstrating superior sensitivity over traditional [18F]FDG PET/CT. These findings suggest a potential shift in standard oncology imaging protocols to better identify metastatic lesions.
Patients undergoing liver cancer evaluations may benefit from more precise staging, potentially leading to more effective personalized treatment plans. This diagnostic precision can help clinicians avoid overlooking distant metastases that might otherwise remain undetected by standard imaging.
The takeaway
Advanced molecular imaging tools like [18F]FAPI PET/CT continue to outperform legacy scans in identifying the full extent of liver cancer spread. Patients should consult with their oncologists to determine if more sensitive diagnostic technologies are appropriate for their specific staging requirements.
Further reading
For more information on the latest research and diagnostic tools, visit our Cancer section.
More information
View the full clinical trial registration information for further study details.
Live Poll
Should medical systems prioritize new PET scanning technologies to improve cancer staging and treatment planning?
